Journal article icon

Journal article

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

Abstract:

Recurrent mutations in isocitrate dehydrogenase 2 (IDH2) occur in ∼12% of patients with acute myeloid leukemia (AML). Mutated IDH2 proteins neomorphically synthesize 2-hydroxyglutarate resulting in DNA and histone hypermethylation, which leads to blocked cellular differentiation. Enasidenib (AG-221/CC-90007) is a first-in-class, oral, selective inhibitor of mutant-IDH2 enzymes. This first-in-human phase 1/2 study assessed the maximum tolerated dose (MTD), pharmacokinetic and pharmacodynamic p...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Accepted Manuscript

Actions


Access Document


Files:
Publisher copy:
10.1182/blood-2017-04-779405

Authors


DiNardo, CD More by this author
Pollyea, DA More by this author
Expand authors...
Publisher:
American Society of Hematology Publisher's website
Journal:
Blood Journal website
Volume:
130
Issue:
6
Pages:
722-731
Publication date:
2017-06-06
Acceptance date:
2017-05-19
DOI:
EISSN:
1528-0020
ISSN:
0006-4971
Pubs id:
pubs:699355
URN:
uri:0d4137c0-dbff-4bfc-ad82-78cecc6ca2bb
UUID:
uuid:0d4137c0-dbff-4bfc-ad82-78cecc6ca2bb
Local pid:
pubs:699355
Language:
English

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP